TrialThe journal of headache and pain2023

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.

Jiying Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.